ASPHALION is participating in the 23rd ASGCT herapy Annual Meeting organized by the American Society of Gene & Cell Therapy.
As international SME Drug Development and Regulatory Affairs Consultancy, we have broad experience dealing with ATMPs and Biologics giving strategic regulatory and scientific advice in preclinical, clinical or CMC aspects from early development to clinical stages and MA procedures. We have experience in different products such as CAR-T cells, autologous and allogenic expanded stem cells, mesenchymal stem cells, oncolytic virus, AAV, plasmids, among others.
Our consultants are experts in their field and are in direct contact with FDA and EU agencies for the development and implementation of new regulatory standards.
Lidia Cánovas, Oriol Penon and Christopher Mann will be fully available during this meeting to answer your questions and doubts.
#ASGCT20 #genetherapy
La mejor actitud que podemos adoptar es la de trat...
El equipo de investigadores observó cambios en el...
El gen AtCDF3 promueve una mayor producción de az...
En nuestro post hablamos sobre este interesante tipo de célula del si...
Curapath se complace en reconocer el importante avance logrado por Mac...
